drugset / Trial / NCT06250205

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

NCT06250205

Phase 1 Completed 30 enrolled NewAmsterdam Pharma Novum · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.

Timeline

Start
2024-02-05
Primary completion
2024-04-25
Completion
2024-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Obicetrapib Small molecule 10 mg Oral
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 0.02 mg Oral

Indications

No indication recorded.